Rocket Pharmaceuticals (RCKT) Operating Leases: 2019-2025
Historic Operating Leases for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Sep 2025 value amounting to $2.8 million.
- Rocket Pharmaceuticals' Operating Leases fell 19.19% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 19.19%. This contributed to the annual value of $3.3 million for FY2024, which is 9.59% up from last year.
- As of Q3 2025, Rocket Pharmaceuticals' Operating Leases stood at $2.8 million, which was down 5.81% from $2.9 million recorded in Q2 2025.
- Rocket Pharmaceuticals' 5-year Operating Leases high stood at $3.7 million for Q1 2024, and its period low was $492,000 during Q3 2022.
- For the 3-year period, Rocket Pharmaceuticals' Operating Leases averaged around $3.2 million, with its median value being $3.1 million (2025).
- In the last 5 years, Rocket Pharmaceuticals' Operating Leases tumbled by 44.78% in 2022 and then spiked by 507.72% in 2023.
- Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Operating Leases stood at $905,000 in 2021, then rose by 20.22% to $1.1 million in 2022, then surged by 173.25% to $3.0 million in 2023, then climbed by 9.59% to $3.3 million in 2024, then fell by 19.19% to $2.8 million in 2025.
- Its Operating Leases stands at $2.8 million for Q3 2025, versus $2.9 million for Q2 2025 and $3.1 million for Q1 2025.